The response to sulpiride in major depression before and after cognitive behavioural therapy: D2 receptor function

Acta Neuropsychiatrica

Volumn 20, Issue 4, 2008, Pages 199-206

  Bell, Caroline ^a   Bhika, Shamina ^a   Porter, Richard ^a   Frampton, Chris ^a   Carter, Janet ^a   McIntosh, Virginia ^a   Jordan, Jenny ^a   Joyce, Peter ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cognitive behavioural therapy; Depression; Dopamine; Sulpiride

Indexed keywords

DOPAMINE 2 RECEPTOR; PROLACTIN; SULPIRIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PROTEIN FUNCTION; PSYCHOLOGIC TEST; TREATMENT RESPONSE;

EID: 47649104717     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2008.00284.x     Document Type: Article

References (52)

1. D'Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000 405 : 365 373.
2. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007 64 : 327 337.
3. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992 149 : 443 454.
4. Rogers MA, Bradshaw JL, Pantelis C, Phillips JG. Frontostriatal deficits in unipolar major depression. Brain Res Bull 1998 47 : 297 310.
5. Bressan RA, Costa DC, Jones HM, Ell PJ, Pilowsky LS. Typical antipsychotic drugs - D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002 56 : 31 36.
6. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004 161 : 564 566.
7. Tremblay LK, Naranjo CA, Graham SJ et al. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry 2005 62 : 1228 1236.
8. Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE. Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry 2002 59 : 409 416.
9. Papp M, Klimek V, Willner P. Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology (Berl) 1994 115 : 441 446.
10. Willner P, Muscat R, Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 1992 16 : 525 534.
11. Willner P, Lappas S, Cheeta S, Muscat R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology 1994 115 : 454 462.
12. Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol Psychiatry 1992 32 : 1 17.
13. Maj J, Papp M, Skuza G, Bigajska K, Zazula M. The influence of repeated treatment with imipramine, (+)- and (-)-oxaprotiline on behavioural effects of dopamine D-1 and D-2 agonists. J Neural Transm 1989 76 : 29 38.
14. Willner P. Dopamine and depression. In : Di Chiara G, ed. Handbook of experimental pharmacology: dopamine in the CNS. Berlin : Springer, 2002 387 416.
15. Collu M, Poggiu AS, Devoto P, Serra G. Behavioural sensitization of mesolimbic dopamine D2 receptors in chronic fluoxetine-treated rats. Eur J Pharmacol 1997 322 : 123 127.
16. Smith TD, Kuczenski R, George-Friedman K, Malley JD, Foote SL. In vivo microdialysis assessment of extracellular serotonin and dopamine levels in awake monkeys during sustained fluoxetine administration. Synapse 2000 38 : 460 470.
17. D'Aquila PS, Peana AT, Panin F, Grixoni C, Cossu M, Serra G. Reversal of antidepressant-induced dopaminergic behavioural supersensitivity after long-term chronic imipramine withdrawal. Eur J Pharmacol 2003 458 : 129 134.
18. Sampson D, Willner P, Muscat R. Reversal of antidepressant action by dopamine antagonists in an animal model of depression. Psychopharmacology 1991 104 : 491 495.
19. Willner P, Papp M. Animal models to detect antidepressants: are new strategies necessary to detect new agents? In : Skolnick P, ed. Antidepressants: new pharmacological strategies. Totowa : Humana, 1997 213 234.
20. Mendels J, Frazer A, Fitzgerald RG, Ramsey TA, Stokes JW. Biogenic amine metabolites in cerebrospinal fluid of depressed and manic patients. Science 1972 175 : 1380 1382.
21. Korf J, van Praag HM. Retarded depression and the dopamine metabolism. Psychopharmacologia 1971 19 : 199 203.
22. Post RM, Kotin J, Goodwin FK, Gordon EK. Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness. Am J Psychiatry 1973 130 : 67 72.
23. Lambert G, Johansson M, Agren H, Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry 2000 57 : 787 793.
24. 2 receptor in depression. Eur Neuropsychopharmacol 2001 11 : 215 220.
25. Joyce PR, Donald RA, Livesey JH, Abbott RM. The prolactin response to metoclopramide is increased in depression and in euthymic rapid cycling bipolar patients. Biol Psychiatry 1987 22 : 508 512.
26. McPherson H, Walsh A, Silverstone T. Growth hormone and prolactin response to apomorphine in bipolar and unipolar depression. J Affect Disord 2003 76 : 121 125.
27. Anderson IM, Cowen PJ. Prolactin response to the dopamine antagonist, metoclopramide, in depression. Biol Psychiatry 1991 30 : 313 316.
28. D'Haenen HA, Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 1994 35 : 128 132.
29. Shah PJ, Ogilvie AD, Goodwin GM, Embeier KP. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med 1997 27 : 1247 1256.
30. Ebert D, Feistel H, Loew T, Pirner A. Dopamine and depression - striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology 1996 126 : 91 94.
31. Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W. Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res 1999 90 : 91 101.
32. 2 receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 2001 50 : 313 322.
33. Meyer JH, McNeely HE, Sagrati S et al. Elevated putamen D2 receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry 2006 163 : 1594 1602.
34. Ebert D, Kaschka W, Stegbauer P, Schrell U. Prolactin response to sulpiride before and after sleep deprivation in depression. Biol Psychiatry 1993 33 : 666 669.
35. Larish R, Klimke A, Vosberg H, Loffler S, Gaebel W, Muller-Gartner HW. In vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulated gyrus in major depression. Neuroimage 1997 5 : 251 260.
36. Willner P, Hale AS, Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord 2005 86 : 37 45.
37. de Koning P, de Vries MH. A comparison of the neuro-endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers. Br J Clin Pharmacol 1995 39 : 7 14.
38. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I/P, version 2.0, 8/98 revision). New York : Biometrics Research Department, New York State Psychiatric Institute, 1998.
39. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960 23 : 56 62.
40. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979 134 : 382 389.
41. McNair DM, Lorr M, Droppleman LF. Manual of the Profile of Mood States. San Diego : Educational and Industrial Testing Service, 1971.
42. Spielberger C, Gorsuch R, Lushene R. Manual for the State Trait Anxiety Inventory. Palo Alto : Consulting Psychologists Press, 1970.
43. Heinz A, Schmidt LG, Reischies FM. Anhedonia in schizophrenic, depressed, or alcohol-dependent patients-neurobiological correlates. Pharmacopsychiatry 1994 27 : 7 10.
44. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995 167 : 99 103.
45. Gerlach J, Korsgaard S, Clemmesen P et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand 1993 87 : 244 252.
46. von Bahr C, Wiesel FA, Movin G et al. Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers. Psychopharmacology 1991 103 : 443 448.
47. Mehta MA, Sahakian BJ, McKenna PJ, Robbins TW. Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology 1999 146 : 162 174.
48. Ueda N, Yoshimura R, Shinkai K, Nakamura J. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry 2002 35 : 175 181.
49. Bocchetta A, Bernardi F, Burrai C, Pedditzi M, Del Zompo M. A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatr Scand 1993 88 : 434 439.
50. Standish-Barry HM, Bouras N, Bridges PK, Watson JP. A randomized double blind group comparative study of sulpiride and amitriptyline in affective disorder. Psychopharmacology 1983 81 : 258 260.
51. Pani L, Gessa GL. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Mol Psychiatry 2002 7 : 247 253.
52. Beck AT, Shaw BF, Emery G. Cognitive therapy of depression. New York : Guilford Press, 1979.